Profitability
Weight: 25%
C-
48
- 5yr Avg ROIC 3.1%
- Operating Margin Trend +16.17 pp/yr
RIGL
Rigel Pharmaceuticals, Inc.
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
⚠ 3 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a platform & compounding fcf business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
C+
60
- 5yr Avg ROE 14.5%
- 5yr Share-Count CAGR 2.5%
Growth Quality
Weight: 25%
A
91
- 5yr Revenue CAGR 18.5%
- 5yr EPS CAGR 1867.7%
- Revenue-Growth Years (5) 3/5
Cash Generation
Weight: 20%
C-
45
- 5yr FCF Margin -6.6%
- 5yr FCF/NI Conversion 0.99x
Balance Sheet
Weight: 10%
A-
84
- Net Debt / EBITDA -0.77x
- Interest Coverage (EBIT/Int) 17.64x
- Altman Z-Score 2.04
Stability
Weight: 5%
A-
80
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 6
- Negative-Revenue Years (5) 2/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.1 of 2 gurus held; 1 added; 1 full exit.
- Holders
- 1 -1
- Avg Δ position
- +5.0%
- New buys
- 0
- Full exits
- 1
- Greenblatt sold -100%
- Cooperman increased +5%